Karyopharm Therapeutics(US:KPTI)2025-05-12 20:06Financial Performance - Total revenue for Q1 2025 was $30.0 million, a decrease from $33.1 million in Q1 2024[14] - U.S. net product revenue for Q1 2025 was $21.1 million, down from $26.0 million in Q1 2024, impacted by a $5.0 million increase in product return reserve[15] - Total revenue for Q1 2025 was $30.015 million, a decrease of 9.5% from $33.126 million in Q1 2024[38] - Product revenue, net for Q1 2025 was $21.054 million, down from $26.006 million in Q1 2024, reflecting a decline of 19.1%[38] - Karyopharm reported a net loss of $23.5 million, or $2.77 per share, for Q1 2025, compared to a net loss of $37.4 million, or $4.85 per share, for Q1 2024[23] - Net loss for Q1 2025 was $23.462 million, compared to a net loss of $37.362 million in Q1 2024, representing a 37.1% improvement[38] - Basic and diluted net loss per share for Q1 2025 was $2.77, improved from $4.85 in Q1 2024[38] Revenue Guidance - Karyopharm reaffirms full-year 2025 total revenue guidance of $140 million to $155 million, including U.S. XPOVIO net product revenue guidance of $115 million to $130 million[17] Expenses - R&D expenses for Q1 2025 were $34.6 million, slightly down from $35.4 million in Q1 2024[19] - Research and development expenses for Q1 2025 were $34.618 million, slightly down from $35.425 million in Q1 2024[38] - SG&A expenses for Q1 2025 were $27.4 million, down from $29.5 million in Q1 2024, due to cost reduction initiatives[20] - Selling, general and administrative expenses decreased to $27.352 million in Q1 2025 from $29.549 million in Q1 2024, a reduction of 7.4%[38] Cash and Assets - Cash, cash equivalents, and investments totaled $70.3 million as of March 31, 2025, down from $109.1 million as of December 31, 2024[24] - Cash, cash equivalents, and investments decreased to $69.941 million as of March 31, 2025, down from $108.712 million at the end of 2024[40] - Total assets decreased to $127.711 million as of March 31, 2025, compared to $164.418 million at the end of 2024[40] - Total liabilities were $333.595 million as of March 31, 2025, down from $350.435 million at the end of 2024[40] Product Demand and Pipeline - Demand for XPOVIO increased by 5% in Q1 2025 compared to Q1 2024, with growth in both community and academic settings[5] - Royalty revenue increased by 57% to $1.7 million in Q1 2025 compared to Q1 2024 due to expanded global patient access for selinexor[5] - Karyopharm is focused on expanding its pipeline targeting high unmet need cancers, including multiple myeloma and diffuse large B-cell lymphoma[33] Clinical Trials - The Phase 3 SENTRY trial is approximately 80% enrolled, with target enrollment expected in June/July 2025[1]